Protocol Ledger

NCT03963232 · Phase III · COMPLETED

A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine

Interventional Phase III clinical trial protocol NCT03963232 sponsored by Eli Lilly and Company in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-07-30 Enrollment: 520 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03963232
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)520 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03963232
Protocol FieldVerified Registry Value
NCT IdentifierNCT03963232
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment520 participants (ACTUAL)
Registered Start Date2019-07-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03963232
Hospital Research SiteLocationSite Profile
Xuanwu Hospital Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->
Chinese PLA General HospitalBeijing, ChinaOpen Hospital Dossier ->
Guangzhou First People's HospitalGuangzhou, ChinaOpen Hospital Dossier ->
Wuhan Union HospitalWuhan, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI